Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of nirogacestat versus placebo in progressing desmoid tumors/aggressive fibromatosis
2018-001991-39Phase 3Unknown
- Sponsor
- SpringWorks Therapeutics
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in aggressive fibromatosis (AF) comparing Nirogacestat with Placebo (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
nirogacestat
03
Conditions
aggressive fibromatosis (AF)
Beyond the preview
Go deeper on 2018-001991-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001991-39.